CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages
Table 4
Comparison of HE4, CA125, ROMA, and CPH-I among BOT I+II and EOC I+II group stratification by pathology.
BOT I+II
EOC I+II
Serous
Mucinous
Endometrioid
Clear cell
Serous
Mucinous
Endometrioid
Clear cell
HE4 (pmol/L)
49.8 (42.5-57.9)
45.3 (38.9-53.0)
57.4 (47.4-89.9)
37.8 (31.5-42.7)
130.6 (72.6-230.5)
57.3 (47.3-65.1)
91.9 (55.6-221.0)
64.8 (50.6-82.3)
CA125 (U/mL)
39.4 (19.6-86.5)
25.5 (17.9-37.2)
54.2 (24.8-127.3)
29.6 (22.7-53.5)
105.8 (55.5-392.9)
54.7 (16.0-117.8)
103.5 (32.1-251.8)
95.1 (34.5-180.3)
ROMA (%)
8.2 (5.5-12.5)
6.1 (4.2-9.6)
11.0 (7.0-43.8)
8.59 (3.0-18.4)
59.7 (23.5-81.9)
11.2 (7.1-14.0)#
45.1 (10.6-82.0)
21.2 (9.4-32.0)
CPH-I (%)
1.8 (1.2-4.6)
1.0 (0.6-2.0)
1.9 (1.4-11.4)
1.5 (0.9-2.3)
30.4 (7.8-56.1)
3.0 (1.7-7.9)
11.4 (2.5-57.0)
7.3 (3.1-14.6)
Note: data are presented as the median (interquartile range). and # EOC I+II vs. BOT I+II in corresponding subgroups. Abbreviations: BOT I+II = borderline ovarian tumors in FIGO stages I and II; EOC I+II = epithelial ovarian cancer in FIGO stages I and II.